NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 240 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1998.
Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 240 (ioversol) is an injectable radiographic contrast agent used to enhance X-ray imaging and visualization during diagnostic imaging procedures. It works through X-ray contrast activity, improving the visibility of internal structures during radiologic examinations. The drug is administered via injection at the point of imaging.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests contracting commercial team and defensive market positioning strategy.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIRAY 240 offers limited career growth opportunity given its mature LOE-approaching status and zero linked job openings. Roles focus on defensive market management and transition planning rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on OPTIRAY 240 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.